Will Japan Pharma Fall In Line With R&D Externalization Trends?
Japanese pharma companies are generally following the same trends as their global counterparts when it comes to the externalization of R&D, and revenues from internal projects are set to fall over the next few years, with Takeda in particular expected to look much more to external opportunities.
You may also be interested in...
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.